Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats

Citation
H. Tozaki et al., Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats, LIFE SCI, 64(13), 1999, pp. 1155-1162
Citations number
8
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Biochemistry & Biophysics
Journal title
LIFE SCIENCES
ISSN journal
0024-3205 → ACNP
Volume
64
Issue
13
Year of publication
1999
Pages
1155 - 1162
Database
ISI
SICI code
0024-3205(19990219)64:13<1155:CDORAN>2.0.ZU;2-E
Abstract
The objective of this study was to estimate the therapeutic effects of R680 70, a new thromboxane synthase inhibitor, on 2,4,6-trinitrobenzenesulfonic acid sodium salt (TNBS)-induced ulcerative colitis in rats. We also examine d the acceleration of the healing effect of R68070 with chitosan capsules t o achieve its colon-specific delivery. The colonic injury and inflammation were assessed by measuring the myeloperoxidase (MPO) activities, colon wet weight/body weight (C/B) ratio and the damage score, respectively. These ma rkers were decreased by the oral administration of R68070 with chitosan cap sules and carboxymethyl-cellulose (CMC) suspension. The therapeutic effects of R68070 against ulcerative colitis were observed in both dosage forms in a dose dependent manner. In addition, its therapeutic effects were increas ed by the use of chitosan capsules, compared with CMC suspension. These res ults suggest that chitosan capsule might be a very useful dosage form for t he colon-specific delivery of R68070 as an antiinflammatory drug and for th e therapy of ulcerative colitis.